Sectors
ORKA
Oruka Therapeutics, Inc.
90.99
2 x 71.53
1 x 126.45
bid
ask
-
0.16
0.17%
02:09 PM
timesize
| Ytd | 200.20% | |
| 1y | 514.80% |
86.00
day range
91.90
14.67
52 week range
115.52
| Open | 91.00 | Prev Close | 91.14 | Low | 86.00 | High | 91.90 | Mkt Cap | 6.02B |
| Vol | 514.55K | Avg Vol | 1.21M | EPS | -2.04 | P/E | N/A | Forward P/E | -32.17 |
| Beta | -0.34 | Short Ratio | 9.52 | Inst. Own | 116.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 94.34 | 200-d Avg | 56.59 | 1yr Est | 153.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.58 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.51 | -0.55 | -0.04 | -7.32% |
| 2026-05-13 | 2026-03 | -0.55 | -0.48 | 0.07 | 12.24% |
| 2026-03-12 | 2025-12 | -0.61 | -0.45 | 0.16 | 26.23% |
| 2025-11-12 | 2025-09 | -0.56 | -0.55 | 0.01 | 1.79% |
| 2025-08-11 | 2025-06 | -0.48 | -0.46 | 0.02 | 4.17% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-11 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-11 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-11 | BTIG | Upgrade | Buy | Buy |
| 2026-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-13 | BTIG | Upgrade | Buy | Buy |
| 2026-07-01 | UBS | Upgrade | Buy | Buy |
Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-12 | AGARWAL ARJUN | Officer | 15.31K | Sale |
| 2026-06-11 | DAMBKOWSKI CARL | Director | 38.74K | Sale |
| 2026-08-23 | EDWARDS LARRY TODD | Officer | 100.00K | Stock Award(Grant) |
| 2026-06-30 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-08-16 | GONCALVES JOANA | Officer | 32.72K | Sale |
| 2026-06-14 | KLEIN LAWRENCE OTTO | Chief Executive Officer | 925.58K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 9.06M | 825.56M | 13.68% |
| 2026-06-29 | Blackrock Inc. | 4.99M | 454.83M | 7.54% |
| 2026-06-29 | Venrock Adviser, LLC | 4.15M | 378.11M | 6.27% |
| 2026-06-29 | Fairmount Funds Management LLC | 3.71M | 337.72M | 5.60% |
| 2026-06-29 | Capital World Investors | 3.40M | 310.04M | 5.14% |
| 2026-06-29 | RTW Investments LP | 3.14M | 286.11M | 4.74% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.55M | 141.21M | 2.34% |
| 2026-06-29 | SmallCap World Fund Inc | 1.53M | 139.23M | 2.31% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 125.30M | 2.08% |
| 2026-06-29 | New Economy Fund | 1.32M | 120.61M | 2.00% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.30M | 118.51M | 1.96% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.26M | 114.89M | 1.90% |
Dividend
| Dividend | Date |
|---|---|
| 1.613 | 2024-08-29 |